Anixa Biosciences Inc (ANIX) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$10.9M, or -$0.34 per diluted share. Operating activities generated -$7.2M of cash. At fiscal year end, Anixa Biosciences held $16.1M in total assets against $2.1M in total liabilities, including $1.2M of cash and equivalents.
Open the full interactive Anixa Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Anixa Biosciences Key Stats
| Share Price | $2.67 |
|---|---|
| Market Cap | $91.3M |
| 52-Week Range | $2.35 – $5.22 |
| Shares Outstanding | 34.2 million (basic, 2026 Q3) |
Anixa Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $512,500 | — | $210,000 | $210,000 | — |
| Cost of Goods Sold | — | $13.6M | — | $11.2M | — | — |
| Gross Profit | — | -$13.1M | — | -$11.0M | — | — |
| Operating Income | -$10.0M | -$13.1M | -$13.9M | -$11.0M | -$13.8M | -$11.7M |
| Pre-Tax Income | -$10.0M | -$13.0M | -$13.6M | -$9.8M | -$12.6M | -$10.9M |
| Net Income | -$10.0M | -$13.0M | -$13.6M | -$9.8M | -$12.6M | -$10.9M |
| Diluted EPS | -$0.45 | -$0.45 | -$0.45 | $0.32 | -$0.39 | -$0.34 |
Anixa Biosciences Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Net Income | -$2.7M | -$2.6M | -$2.5M | -$2.6M |
| Diluted EPS | -$0.08 | -$0.08 | -$0.07 | -$0.08 |
Anixa Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.4M | $29.1M | $12.4M | $915,000 | $1.3M | $1.2M |
| Current Assets | $9.4M | $36.0M | $30.2M | $25.4M | $21.4M | $15.9M |
| Total Assets | $9.5M | $36.3M | $30.4M | $25.5M | $21.6M | $16.1M |
| Current Liabilities | $1.2M | $1.3M | $2.0M | $2.0M | $2.5M | $2.0M |
| Total Liabilities | $691,608 | $1.5M | $2.2M | $2.2M | $2.7M | $2.1M |
| Shareholders' Equity | $8.8M | $35.4M | $29.0M | $24.3M | $20.0M | $15.2M |
Anixa Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$6.2M | -$4.9M | -$6.5M | -$6.2M | -$7.3M | -$7.2M |
| Cash From Investing | -$305,791 | -$3.9M | -$10.7M | -$5.6M | $4.3M | $4.9M |
| Cash From Financing | $9.4M | $31.6M | $452,000 | $366,000 | $3.4M | $2.3M |
| Free Cash Flow | -$6.2M | -$5.0M | — | — | — | — |
Figures from Anixa Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Anixa Biosciences financials page for every line item.
Anixa Biosciences Company Profile
| Ticker | ANIX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Jose, California |
| Incorporated in | Delaware |
| Fiscal Year End | October 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000715446 |
Frequently Asked Questions
What is Anixa Biosciences' annual revenue history?
Anixa Biosciences' annual revenue by fiscal year: 2021: $512,500; 2023: $210,000; 2024: $210,000.
What was Anixa Biosciences' net income in fiscal 2025?
Anixa Biosciences reported net income of -$10.9M for fiscal 2025.
What was Anixa Biosciences' earnings per share (EPS) in fiscal 2025?
Anixa Biosciences' diluted EPS was -$0.34 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Anixa Biosciences are outstanding?
Anixa Biosciences reported a weighted average of 34.2 million basic shares outstanding in 2026 Q3.
What is Anixa Biosciences' market cap?
Based on its latest closing price, Anixa Biosciences (ANIX) has a market capitalization of about $91.3M.
When does Anixa Biosciences' fiscal year end?
Anixa Biosciences' fiscal year end, as registered with the SEC, is October 31.
Where is Anixa Biosciences headquartered?
Anixa Biosciences lists its business address in San Jose, California in its SEC filings.